|Shakespeare's three witches in Macbeth: |
life sciences, but no available patents ...
Life sciences have been mired in controversy in the European Union since most of today's patent practitioners can remember. Directive 98/44 on the legal protection of biotechnological inventions -- the so-called "Biotech Directive" -- started off as a proposal some ten years earlier, and even after its passage it was subjected to a fearsome legal challenge from the Netherlands in Case C-377/98 that was not resolved until late 2001. Ever since then, pretty well every aspect of the patentability of life forms has been discussed, debated, dissected and diced in judicial or office proceedings [if you require further persuasion, recent Katposts touching on life science issues may be perused here, here and here].
for patent owners
These topics are among the fare offered in C5's forthcoming Life Sciences IP Summit 2014 (which this weblog is, somewhat belatedly, partnering). Subtitled "Powering Business Growth through Practical and Innovative Patent Monetisation and Protection Strategies", this event is destined to address some of the most sensitive issues in the life sciences sector, and more besides. While it's described as a "Summit", the event actually starts in the foothills with a brace of pre-conference afternoon workshops (hoe to develop and cultivate a "free-to-operate" strategy and how to craft agreements that limit the potential for future litigation). If their synopses are an indication of their content, they will indeed require participants to do some work. The programme then ascends to the summit through a familiar list of nightmare-inducing issues, together with some relatively light though deadly serious entertainment in the form of a mock trial and some no doubt amusing speculation as to how the life sciences patent ecology might be affected by the shift to the new unitary patent and unified patent court.
|Maybe I'm naive, says|
Merpel, but I still can't
see the point of a
Red Light district ...
A matter of life and death here
More important than life and death? Bill Shankly here